ImmunityBio (IBRX) was a top loser this quarter, falling -18.95%. Expect a Downtrend continuation
ImmunityBio (IBRX) has had a tough quarter, falling by almost 19%. Despite this, there may be some hope for the stock, as the Aroon Indicator has recently triggered a bullish signal.
First, let's take a look at the earnings results for ImmunityBio. Unfortunately, there is no specific mention of earnings in the provided information. However, it is important to note that earnings reports can greatly impact the stock price of a company. A company's earnings can affect its stock price in a few ways. Positive earnings can lead to an increase in demand for a stock, while negative earnings can lead to a decrease in demand.
Moving on to the technical analysis, the Aroon Indicator is a popular indicator that can help traders identify potential changes in trend. It consists of two lines: the AroonUp line, which measures the strength of the uptrend, and the AroonDown line, which measures the strength of the downtrend. When the AroonUp line crosses above the AroonDown line, it is a bullish signal.
According to the provided information, IBRX's Aroon Indicator triggered a bullish signal on May 01, 2023. This means that the AroonUp line is above 70 while the AroonDown line is below 30, indicating that the stock could be setting up for a bullish move. In fact, historical data shows that in 168 of 188 similar instances where the Aroon Indicator showed a similar pattern, the stock moved higher in the days that followed, putting the odds of a move higher at 89%.
However, it is important to note that past performance is not always indicative of future results. While the Aroon Indicator may be indicating a potential move higher for IBRX, there are other factors that could impact the stock's performance. Additionally, the odds of a downtrend continuation for IBRX are relatively high at 58%.
While the recent Aroon Indicator signal may be a positive sign for IBRX, it is important for investors to consider all available information before making any investment decisions. The stock has had a tough quarter, and while historical data suggests a potential move higher, there are still risks involved.
IBRX in +7.82% Uptrend, growing for three consecutive days on July 02, 2026
Moving higher for three straight days is viewed as a bullish sign. Keep an eye on this stock for future growth. Considering data from situations where IBRX advanced for three days, in of 241 cases, the price rose further within the following month. The odds of a continued upward trend are .
Technical Analysis (Indicators)
Bullish Trend Analysis
The Momentum Indicator moved above the 0 level on June 18, 2026. You may want to consider a long position or call options on IBRX as a result. In of 101 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are .
The Moving Average Convergence Divergence (MACD) for IBRX just turned positive on June 22, 2026. Looking at past instances where IBRX's MACD turned positive, the stock continued to rise in of 55 cases over the following month. The odds of a continued upward trend are .
IBRX moved above its 50-day moving average on June 24, 2026 date and that indicates a change from a downward trend to an upward trend.
The 10-day moving average for IBRX crossed bullishly above the 50-day moving average on June 30, 2026. This indicates that the trend has shifted higher and could be considered a buy signal. In of 16 past instances when the 10-day crossed above the 50-day, the stock continued to move higher over the following month. The odds of a continued upward trend are .
Bearish Trend Analysis
The 10-day RSI Indicator for IBRX moved out of overbought territory on July 06, 2026. This could be a bearish sign for the stock. Traders may want to consider selling the stock or buying put options. Tickeron's A.I.dvisor looked at 19 similar instances where the indicator moved out of overbought territory. In of the 19 cases, the stock moved lower in the following days. This puts the odds of a move lower at .
The Stochastic Oscillator may be shifting from an upward trend to a downward trend. In of 48 cases where IBRX's Stochastic Oscillator exited the overbought zone, the price fell further within the following month. The odds of a continued downward trend are .
IBRX broke above its upper Bollinger Band on June 24, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.
The Aroon Indicator for IBRX entered a downward trend on June 25, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
Fundamental Analysis (Ratings)
The Tickeron Valuation Rating of (best 1 - 100 worst) indicates that the company is seriously undervalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (0.000) is normal, around the industry mean (22.980). P/E Ratio (0.000) is within average values for comparable stocks, (38.292). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (2.534). IBRX has a moderately low Dividend Yield (0.000) as compared to the industry average of (0.038). P/S Ratio (60.241) is also within normal values, averaging (407.380).
The Tickeron Price Growth Rating for this company is (best 1 - 100 worst), indicating steady price growth. IBRX’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron PE Growth Rating for this company is (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron SMR rating for this company is (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is (best 1 - 100 worst), indicating that the returns do not compensate for the risks. IBRX’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 93, placing this stock worse than average.
Notable companies
Industry description
Market Cap
High and low price notable news
Volume
Fundamental Analysis Ratings
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
Advertisement
General Information
a producer of cancer treatment products
Industry Biotechnology
Advertisement